Predicted protein targets (top 4)
| gene | UniProt | supporting neighbours | confidence | |
|---|---|---|---|---|
| ▸ | ADORA3 | P0DMS8 | 11/20 | 0.58 |
| ▸ | ADORA2A | P29274 | 9/20 | 0.55 |
| ▸ | ADORA1 | P30542 | 8/20 | 0.55 |
| ▸ | ADORA2B | P29275 | 2/20 | 0.55 |
Click a target to see other patent compounds predicted against it — the reverse direction, in place.
Similar compounds — the chemically nearest patent molecules
Nearest neighbours by Morgan-fingerprint cosine across the patent-compound collection, with each neighbour's top predicted target and the predicted targets it shares with this molecule.
| Compound | similarity | top predicted | shared targets | |
|---|---|---|---|---|
| SCHEMBL3055654 | 1.00 | ADORA3 (0.58) | ADORA3ADORA2AADORA1ADORA2B | |
| SCHEMBL29501856 | 1.00 | ADORA3 (0.58) | ADORA3ADORA2AADORA1ADORA2B | |
| SCHEMBL29501809 | 0.85 | ADORA3 (0.59) | ADORA3ADORA2AADORA1ADORA2B | |
| SCHEMBL6013498 | 0.80 | ADORA3 (0.68) | ADORA3ADORA2AADORA1ADORA2B | |
| SCHEMBL29501915 | 0.79 | ADORA2A (0.53) | ADORA3ADORA2AADORA1ADORA2B | |
| SCHEMBL22349409 | 0.78 | CDK1 (0.73) | ADORA3ADORA2AADORA1 | |
| SCHEMBL29501881 | 0.78 | CDK1 (0.73) | ADORA3ADORA2AADORA1 | |
| SCHEMBL8936762 | 0.78 | ADORA3 (0.55) | ADORA3ADORA2AADORA1ADORA2B | |
| SCHEMBL29703267 | 0.76 | PPARG (0.76) | ADORA3ADORA2AADORA1 | |
| SCHEMBL29703231 | 0.76 | PPARG (0.76) | ADORA3ADORA2AADORA1 |
Similarity is cosine over the 2,048-bit Morgan fingerprint (≈ Tanimoto). Identical fingerprints score 1.00.
Patent provenance — the patents this molecule appears in, and who filed them
Claimed or disclosed in 9 patents. claimed = in the patent's claims; disclosed = body only.
| Patent | Title | Assignee | Published | Priority | Filing | Country | Status |
|---|---|---|---|---|---|---|---|
| US-20060084626-A1 | Pharmaceutical compositions comprising an adenosine receptor agonist or antagonist | CAN-FITE BIOPHARMA LTD. (IL) | 2006-04-20 | — | — | US | claimed |
| EP-3380104-B1 | AN A3 ADENOSINE RECEPTOR LIGAND FOR USE IN TREATING ECTOPIC FAT ACCUMULATION | CAN FITE BIOPHARMA LTD (IL) | 2020-11-11 | — | — | EP | disclosed |
| EP-3530273-A2 | A3 ADENOSINE RECEPTOR LIGANDS FOR USE IN TREATMENT OF A SEXUAL DYSFUNCTION | Can-Fite Biopharma Ltd. (IL) | 2019-08-28 | — | — | EP | disclosed |
| US-20100222369-A1 | TREATMENT FOR DRY EYE CONDITIONS | CAN-FITE BIOPHARMA LTD. (IL) | 2010-09-02 | — | — | US | disclosed |
| US-7696150-B2 | Modulation of the activity of an interleukin 17 receptor-related protein, EVI27, and uses thereof | BOARD OF TRUSTEES OF THE UNIVERSITY OF ARKANSAS (US) | 2010-04-13 | — | — | US | disclosed |
| US-7094886-B2 | Evi27 gene sequences and protein encoded thereby | BOARD OF TRUSTEES OF THE UNIVERSITY OF ARKANSAS (US) | 2006-08-22 | — | — | US | disclosed |
| US-20050208572-A1 | EV127 gene sequences and protein encoded thereby | THE BOARD OF TRUSTEES OF THE UNIVERSITY OF ARKANSAS SYSTEM | 2005-09-22 | — | — | US | disclosed |
| US-20020102639-A1 | Evi27 gene sequences and protein encoded thereby | BIOVENTURES, LLC | 2002-08-01 | — | — | US | disclosed |
| WO-2001057202-A2 | EVI27 GENE SEQUENCES AND PROTEIN ENCODED THEREBY | THE BOARD OF TRUSTEES OF THE UNIVERSITY OF ARKANSAS (US) | 2001-08-09 | — | — | WO | disclosed |
Patent text — is the patent's own abstract consistent with the prediction?
For each of this compound's patents that has machine-readable text (2 of them — usually the abstract, not the full specification), we ask MedCPT which protein the text reads most about, and where the chemistry-predicted target lands among 4885 human targets. A high rank means the patent's own wording is consistent with the prediction — a weak, independent signal, not proof of activity.
| Patent | Title | Text reads most about | Predicted target · text-rank |
|---|---|---|---|
| US-20100222369-A1 | TREATMENT FOR DRY EYE CONDITIONS | ADORA3, ADORA2A, ADORA2B | ADORA3 1/4885ADORA2A 2/4885ADORA1 4/4885 |
| US-20060084626-A1 | Pharmaceutical compositions comprising an adenosine receptor agonist or antagonist | ADORA2A, ADORA3, ADORA1 | ADORA3 2/4885ADORA2A 1/4885ADORA1 3/4885 |
“Text reads most about” is the patent abstract's nearest protein in MedCPT space (background-debiased). Only ~1.4% of patents have machine-readable text, so most compounds won't have this panel.